Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

mirxes
TO KNOW. TO ACT.

Mirxes Holding Company Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2629)

VOLUNTARY ANNOUNCEMENT

COMPLETION OF ENROLMENT IN CADENCE CRC

This announcement is made by Mirxes Holding Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business development of the Group.

COMPLETION OF ENROLMENT IN CADENCE CRC

The board (the "**Board**") of directors (the "**Director(s)**") of the Company announces that the Company has completed the enrolment for CADENCE (CAncer Detected Early caN be CurEd) CRC, a large, prospective clinical study designed to validate its blood test for colorectal cancer ("**CRC**") screening in average-and high-risk adults.

With more than 6,000 participants prospectively enrolled across Southeast Asia, CADENCE CRC is the first and largest registrational study in the region evaluating a blood-based colorectal cancer screening test. The study includes participants from diverse racial and ethnic backgrounds including Chinese, Malay and Indian ethnicities, reflecting the real-world population of Southeast Asia and strengthening the generalisability of its findings.

FURTHER INFORMATION ON CADENCE CRC

CADENCE CRC is designed as a prospective validation study to support regulatory and clinical adoption of the Company's CRC screening blood test. Participants undergo standard-of-care colonoscopy as the reference method, enabling rigorous evaluation of clinical performance.

Enrolment first started in 2023 and reached the targeted cohort size of 6,000 in early 2026. Completion of enrolment marks a critical milestone, transitioning the study into final laboratory analysis and data evaluation. The Company expects to report topline results following completion of data analysis and follow-up within 2026.

The blood test evaluated in CADENCE CRC is powered by the Company's proprietary miRNA-centric multi-omics platform, which integrates (i) tumour-originated signals; (ii) non-tumour host-response signals; and (iii) AI-enabled machine learning algorithms. This unique miRNA empowered approach enables improved detection of colorectal cancer at early and potentially curable stages through a simple non-invasive blood draw, addressing persistent barriers to screening uptake associated with stool-based testing and colonoscopy.

CADENCE CRC builds upon prior development studies demonstrating (i) sensitivity exceeding 80% in detecting early stages of CRC; and (ii) specificity of approximately 90%. By prospectively validating these findings in a large Southeast Asian cohort, the study aims to confirm performance in a real-world screening population.

NEXT STEPS AND EXPECTED COMMERCIALISATION PLAN OF CADENCE CRC

Following enrolment completion, the Company will proceed with (i) final sample processing and laboratory analysis; (ii) database lock and statistical validation; (iii) preparation for topline data announcement; (iv) regulatory and market access engagement; and (v) subject to successful study outcomes and applicable regulatory requirements, the Company intends to initiate commercialisation of its CRC blood test as a Laboratory Developed Test ("**LDT**") in Singapore and selected Southeast Asia markets by mid-2026, while concurrently seeking regulatory approval of the test as an In Vitro Diagnostic device.

The planned LDT launch will leverage the Company's existing laboratory infrastructure and regional clinical network in Southeast Asia, enabling early market access while the Company continues to pursue broader regulatory approvals and reimbursement pathways.

The Company believes that introducing a clinically validated, convenient blood-based screening option has the potential to increase participation rates, improve early detection, and reduce colorectal cancer mortality across Asia.

ADDRESSING UNMET SCREENING NEEDS IN ASIA BY CADENCE CRC

Colorectal cancer remains one of the leading causes of cancer-related mortality in Asia, yet screening uptake remains suboptimal in many markets. Across Southeast Asia, an estimated 140 million to 170 million adults aged 45 to 74 fall within recommended colorectal cancer screening age groups, while across Asia the eligible population exceeds 1.2 billion people.

Despite this substantial at-risk population, screening participation rates in many markets remain below optimal levels. Even modest improvements in uptake represent a significant healthcare opportunity, with the addressable screening-test market in Southeast Asia alone estimated to reach several billion U.S. dollars annually depending on screening modality, interval, and pricing. The Company believes that a convenient, clinically validated blood-based screening option could help unlock this large, underserved population and expand access to early detection across the region.

After successful clinical trials and multi-market approval of GASTROClear, the completion of enrolment of CADENCE CRC represents a significant step forward in the Company's mission to advance early cancer detection for the top five most prevalent and deadly cancers in Asia. As Southeast Asia's first and largest registrational study of a blood-based colorectal cancer screening test, CADENCE CRC demonstrates the Company's commitment to generating rigorous clinical evidence.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that we can obtain further approval for, or ultimately develop and market CADENCE CRC successfully.

By Order of the Board
Mirxes Holding Company Limited
Dr. ZHOU Lihan
Executive Director and Chief Executive Officer

Hong Kong, February 23, 2026

As at the date of this announcement, the Board comprises (i) Dr. ZHOU Lihan and Dr. ZOU Ruiyang as executive Directors; (ii) Dr. TOO Heng Phon, Dr. LE Beilin and Mr. LIU Da as non-executive Directors; and (iii) Dr. LAM Sin Lai Judy, Mr. FANG Xiao and Ms. MA Andrea Lo Ling as independent non-executive Directors.